Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Immunity

Volumn 44, Issue 3, 2016, Pages 698-711

  Mlecnik, Bernhard ^a,b,c   Bindea, Gabriela ^a,b,c   Angell, Helen K ^a,b,c,d   Maby, Pauline ^a,b,c,e   Angelova, Mihaela ^a,b,c,f   Tougeron, David ^e,g   Church, Sarah E ^a,b,c   Lafontaine, Lucie ^a,b,c   Fischer, Maria ^f   Fredriksen, Tessa ^a,b,c   Sasso, Maristella ^a,b,c   Bilocq, Amélie M ^a,b,c   Kirilovsky, Amos ^a,b,c   Obenauf, Anna C ^h   Hamieh, Mohamad ^e   Berger, Anne ^a,i   Bruneval, Patrick ⁱ   Tuech, Jean Jacques ^g   Sabourin, Jean Christophe ^g   Le Pessot, Florence ^g   Mauillon, Jacques ^g,j   Rafii, Arash ^k   Laurent Puig, Pierre ^a,b   Speicher, Michael R ^h   Trajanoski, Zlatko ^f   Michel, Pierre ^g   Sesboüe, Richard ^e   Frebourg, Thierry ^a,e   Pagès, Franck ^a,b,c,i   Valge Archer, Viia ^d,l   Latouche, Jean Baptiste ^e,g   Galon, Jérôme ^a,b,c   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY OF ROUEN   (France)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j LE HAVRE HOSPITAL   (France)

^k WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^l MEDIMMUNE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; FRAMESHIFT MUTATION; GENE EXPRESSION; HUMAN; IMMUNOSCORE; MEMORY T LYMPHOCYTE; MICROSATELLITE INSTABILITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCORING SYSTEM; T LYMPHOCYTE; TH1 CELL; AGED; CELL CULTURE; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; CYTOTOXICITY TEST; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; IMMUNOASSAY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE; MOLECULAR PATHOLOGY; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; T LYMPHOCYTE SUBPOPULATION; VERY ELDERLY;

MICROSATELLITE DNA; TRANSCRIPTOME;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA MUTATIONAL ANALYSIS; FEMALE; FRAMESHIFT MUTATION; HUMANS; IMMUNOASSAY; IMMUNOLOGIC MEMORY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TRANSCRIPTOME;

EID: 84960466507     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.02.025     Document Type: Article

References (59)

1. Angell H., Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 2013, 25:261-267.
2. Angelova M., Charoentong P., Hackl H., Fischer M.L., Snajder R., Krogsdam A.M., Waldner M.J., Bindea G., Mlecnik B., Galon J., Trajanoski Z. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015, 16:64.
3. Atreya I., Neurath M.F. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev. Anticancer Ther. 2008, 8:561-572.
4. Bacher J.W., Flanagan L.A., Smalley R.L., Nassif N.A., Burgart L.J., Halberg R.B., Megid W.M., Thibodeau S.N. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis. Markers 2004, 20:237-250.
5. Berghoff A.S., Fuchs E., Ricken G., Mlecnik B., Bindea G., Spanberger T., Hackl M., Widhalm G., Dieckmann K.D., Bilocq A.M., et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology 2016, 5:e1.
6. Bindea G., Mlecnik B., Hackl H., Charoentong P., Tosolini M., Kirilovsky A., Fridman W.H., Pagès F., Trajanoski Z., Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009, 25:1091-1093.
7. Bindea G., Galon J., Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013, 29:661-663.
8. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., Obenauf A.C., Angell H., Fredriksen T., Lafontaine L., Berger A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795.
9. Bindea G., Mlecnik B., Angell H.K., Galon J. The immune landscape of human tumors: Implications for cancer immunotherapy. OncoImmunology 2014, 3:e27456.
10. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
11. Broussard E.K., Disis M.L. TNM staging in colorectal cancer: T is for T cell and M is for memory. J. Clin. Oncol. 2011, 29:601-603.
12. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
13. Church S.E., Galon J. Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. Immunity 2015, 43:631-633.
14. Des Guetz G., Schischmanoff O., Nicolas P., Perret G.Y., Morere J.F., Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 2009, 45:1890-1896.
15. Finn O.J. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol. Res. 2006, 36:73-82.
16. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358:2704-2715.
17. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
18. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
19. Galon J., Pagès F., Marincola F.M., Angell H.K., Thurin M., Lugli A., Zlobec I., Berger A., Bifulco C., Botti G., et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 2012, 10:205.
20. Galon J., Pagès F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., Gajewski T.F., Ascierto P.A. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 2012, 10:1.
21. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
22. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014, 232:199-209.
23. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
24. Gryfe R., Kim H., Hsieh E.T., Aronson M.D., Holowaty E.J., Bull S.B., Redston M., Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000, 342:69-77.
25. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
26. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
27. June C.H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 2007, 117:1204-1212.
28. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372:2509-2520.
29. Llosa N.J., Cruise M., Tam A., Wicks E.C., Hechenbleikner E.M., Taube J.M., Blosser R.L., Fan H., Wang H., Luber B.S., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015, 5:43-51.
30. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24:5313-5327. ASCO.
31. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W.H., Pagès F., Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011, 29:610-618.
32. Mlecnik B., Bindea G., Angell H.K., Sasso M.S., Obenauf A.C., Fredriksen T., Lafontaine L., Bilocq A.M., Kirilovsky A., Tosolini M., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 2014, 6:228ra37.
33. Nagtegaal I.D., Quirke P., Schmoll H.J. Has the new TNM classification for colorectal cancer improved care?. Nat. Rev. Clin. Oncol. 2012, 9:119-123.
34. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., Giovannucci E., Dranoff G., Fuchs C.S., Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 2010, 222:350-366.
35. Ogino S., Nosho K., Irahara N., Meyerhardt J.A., Baba Y., Shima K., Glickman J.N., Ferrone C.R., Mino-Kenudson M., Tanaka N., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 2009, 15:6412-6420.
36. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 2011, 8:711-719.
37. Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
38. Pagès F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27:5944-5951.
39. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
40. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23:609-618.
41. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.
42. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349:247-257.
43. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
44. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160:48-61.
45. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
46. Schumacher T., Bunse L., Pusch S., Sahm F., Wiestler B., Quandt J., Menn O., Osswald M., Oezen I., Ott M., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512:324-327.
47. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13:2498-2504.
48. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
49. Sobin L., Wittekind C. TNM classification of malignant tumors 2002, Wiley-Liss, New York.
50. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
51. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
52. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pagès F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
53. Tougeron D., Maby P., Elie N., Fauquembergue E., Le Pessot F., Cornic M., Sabourin J.C., Michel P., Frébourg T., Latouche J.B. Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. PLoS ONE 2013, 8:e61001.
54. Trautmann K., Terdiman J.P., French A.J., Roydasgupta R., Sein N., Kakar S., Fridlyand J., Snijders A.M., Albertson D.G., Thibodeau S.N., Waldman F.M. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin. Cancer Res. 2006, 12:6379-6385.
55. Vacchelli E., Galluzzi L., Fridman W.H., Galon J., Sautès-Fridman C., Tartour E., Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. OncoImmunology 2012, 1:179-188.
56. Weitz J., Koch M., Debus J., Höhler T., Galle P.R., Büchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
57. Westra J.L., Plukker J.T., Buys C.H., Hofstra R.M. Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. Clin. Colorectal Cancer 2004, 4:252-259.
58. Williams D.S., Bird M.J., Jorissen R.N., Yu Y.L., Walker F., Zhang H.H., Nice E.C., Burgess A.W. Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS ONE 2010, 5:e16012.
59. Zlobec I., Karamitopoulou E., Terracciano L., Piscuoglio S., Iezzi G., Muraro M.G., Spagnoli G., Baker K., Tzankov A., Lugli A. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS ONE 2010, 5:e14282.